- Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.915 |
---|---|
High | 0.915 |
Low | 0.88 |
Bid | 0.92 |
Offer | 0.955 |
Previous close | 0.855 |
Average volume | 238.89 |
---|---|
Shares outstanding | 164.61m |
Free float | 5.58m |
P/E (TTM) | -- |
Market cap | 159.68m USD |
EPS (TTM) | -0.4043 USD |
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼